Exeltis

What Exeltis does

Exeltis is the branded specialty pharmaceutical subsidiary of Spain-based Insud Pharma Group, focused on women's health and central nervous system (CNS) therapeutic areas. Headquartered in Madrid and operating across more than 40 countries in Europe, America, Asia, and Africa, the company employs nearly 4,000 professionals and markets a portfolio of more than 300 pharmaceutical and nutritional specialties, including contraceptives, hormone replacement therapies, fertility treatments, antiepileptics, antidepressants, ADHD medications, and orphan-disease therapies.

The company operates across the full pharmaceutical value chain — from research and development through active pharmaceutical ingredient (API) manufacturing and finished dosage form (FDF) production to commercial distribution — leveraging the integrated capabilities of the parent Insud Pharma group, which also includes Chemo (APIs) and mAbxience (biotech). Distribution is executed through a direct enterprise field-sales model targeting healthcare professionals, pharmacies, and patients globally, supplemented by over-the-counter (OTC) and nutritional product lines for both human and animal care.

Revenue is generated through one-time product sales of branded prescription medicines, OTC products, and nutritional supplements across multiple geographies and therapeutic categories. Recent strategic activity centers on extending the CNS portfolio through rare-disease and orphan-disease licensing partnerships (notably the October 2025 THX Pharma collaboration for Batten-1 and TX01), reinforcing the company's positioning as a global specialist in women's health with a growing CNS footprint.

Name

Exeltis

Legal name

Exeltis Pharmaceuticals Holding, S.L.

Website

https://exeltis.com

Company type

Private

Founded year

2003

Operating status

Operating

Headcount range

1,001–5,000 employees

Ownership category

akta.pro rank

Product category

Women's Health Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industries

Endocrinology & Reproductive Health Pharmaceuticals (incl. Women’s Health) (HLAIAAAJ), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Women's health pharmaceuticals
• CNS therapeutics
• Branded generic medicines
• Gynecological treatments
• OTC medications

Headquarters

HQ city

Madrid

HQ country

Spain

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Operations, Supply Chain, Personnel, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Pharmaceutical product sales: Exeltis generates revenue through the sale of pharmaceutical and nutritional products across its global manufacturing and sales network, including branded medicines, OTC products, and specialized treatments in women's health and CNS therapeutic areas.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Exeltis is a pharmaceutical company within the Insud Pharma Group that researches, develops, manufactures, and commercializes over 300 pharmaceutical and nutritional specialty products worldwide. Its portfolio is anchored in two therapeutic areas: Women's Health (covering gynecology, contraception, menopause, fertility, and pregnancy/postpartum care) and Central Nervous System (antiepileptics, antidepressants, ADHD, neuropathic pain, migraine, Parkinson's, and orphan diseases), with additional OTC and nutritional products distributed across more than 40 countries.

Product overview

Exeltis is a pharmaceutical organization within the Insud Pharma group that develops, manufactures, and commercializes innovative treatments and health products. The company operates two core product portfolios: Women's Health (spanning general gynecology, family planning, menopause, fertility, and pregnancy/postpartum care with products including contraceptives, hormonal therapies, vitamins, and nutritional supplements) and Central Nervous System (covering antiepileptics, antidepressants, ADHD, neuropathic pain, migraine, hypnotics, Parkinson's disease, and orphan diseases). The combined portfolio exceeds 300 pharmaceutical and nutritional specialties distributed across more than 40 countries through a global manufacturing and sales network.

Differentiator

Problem solved

Functional benefit

Products and services

• Women's Health Portfolio
• Central Nervous System (CNS) Portfolio
• Pharmaceutical and Nutritional Specialties

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators4 records

Recent moves4 records

Expansion highlights4 records

Broad incumbents

• AbbVie: Global pharma with significant CNS/neurology (migraine, Parkinson's) and women's-health adjacencies. Comparable at the therapeutic-area level even though scale is an order of magnitude larger.
• Bayer (Pharmaceuticals Division): Multinational incumbent with global franchises in women's health (oral contraceptives, IUDs, menopause) plus CNS. Much larger, but overlaps with Exeltis in target therapeutic categories and physician channels.
• Viatris (Mylan): Large global pharma with women's health, CNS, and branded/specialty portfolios, plus established OTC and nutritional segments. Comparable breadth of therapeutic and distribution coverage.
• Teva Pharmaceutical Industries: Global generics and specialty pharma with significant CNS exposure and women's health products. Comparable in scale, manufacturing footprint, and value-chain scope to Exeltis.
• UCB (Union Chimique Belge): Belgian specialty pharma with strong CNS (epilepsy, Parkinson's) and neurology footprint. Comparable specialty focus and CNS product overlap to Exeltis' CNS portfolio.

Direct peers

• Organon & Co. Pure-play women's-health company spun out of Merck, with established franchises in contraception, fertility, and biosimilars. Direct peer to Exeltis in target therapeutic areas and global GTM model.
• Gedeon Richter: Hungarian-headquartered specialty pharma with a leading women's-health franchise (contraceptives, HRT) plus CNS and biosimilar operations. Highly comparable geographic footprint and therapeutic mix to Exeltis.
• Theramex: Global women's-health specialty pharma focused on contraception, fertility, menopause, and osteoporosis. Closest direct comparable to Exeltis given shared therapeutic niche, global commercial footprint, and mid-sized specialty positioning.

Others

• Chemo (Insud Pharma sister entity): Sister subsidiary of Insud Pharma focused on APIs, generics, and CDMO services. Directly comparable on technology/manufacturing axis, sharing parent resources and overlapping distribution infrastructure with Exeltis.

Regional players

• Italfarmaco: Mid-sized Italian pharma with women's health, neurology, and OTC offerings distributed across Europe and Latin America. Comparable regional scale and therapeutic mix to Exeltis.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/exeltis
• LinkedInlinkedin.com/company/exeltis

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exeltis